InventisBio Co (SHSE:688382) Debt-to-Equity : 0.01 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is InventisBio Co Debt-to-Equity?

InventisBio Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥7.5 Mil. InventisBio Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥2.9 Mil. InventisBio Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥1,934.6 Mil. InventisBio Co's debt to equity for the quarter that ended in Mar. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for InventisBio Co's Debt-to-Equity or its related term are showing as below:

SHSE:688382' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.01 Max: 0.05
Current: 0.01

During the past 6 years, the highest Debt-to-Equity Ratio of InventisBio Co was 0.05. The lowest was 0.01. And the median was 0.01.

SHSE:688382's Debt-to-Equity is ranked better than
99.91% of 1068 companies
in the Biotechnology industry
Industry Median: 0.15 vs SHSE:688382: 0.01

InventisBio Co Debt-to-Equity Historical Data

The historical data trend for InventisBio Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InventisBio Co Debt-to-Equity Chart

InventisBio Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.04

0.01

InventisBio Co Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial												0.01	0.01	0.02	0.01	0.01

Competitive Comparison of InventisBio Co's Debt-to-Equity

For the Biotechnology subindustry, InventisBio Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InventisBio Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InventisBio Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where InventisBio Co's Debt-to-Equity falls into.

InventisBio Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

InventisBio Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(9.004	+	2.615)	/	1997.603
	=	0.01

InventisBio Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.48	+	2.923)	/	1934.636
	=	0.01

InventisBio Co (SHSE:688382) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

InventisBio Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of InventisBio Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

InventisBio Co (SHSE:688382) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InventisBio Co Ltd (SHSE:688382) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 4, Lane 67, Li Bing Road, Room 210, Pilot Free Trade Zone, Shanghai, CHN, 201203

Website

http://www.inventisbio.com

InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.

InventisBio Co (SHSE:688382) Headlines

No Headlines